Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71881 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 24.04.2026. Verfasst von Min-Hsi Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Chest Medicine, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Lung Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kaohsiung Veterans General Hospital.
Abstract (Originalsprache)
Background and Purpose Patients with advanced epidermal growth factor receptor (EGFR)‐mutated adenocarcinoma often receive frontline first‐ and second‐generation EGFR tyrosine kinase inhibitor (TKI) treatments in Taiwan. However, upon progression, not all patients undergo rebiopsy for molecular testing. In some cases, tumors are located in difficult‐to‐access areas, and some rebiopsy specimens are inadequate for pathological and molecular assessment. Our aim is to evaluate the efficacy of the third‐generation EGFR TKI, osimertinib, in tumors with unknown T790M mutation status.
Methods
This study retrospectively collected data from patients with EGFR‐mutant advanced lung adenocarcinoma who received first‐line first‐ or second‐generation EGFR TKI therapy followed by the third‐generation EGFR TKI osimertinib without rebiopsy to assess T790M mutation status between January 2015 and December 2024. Efficacy and survival outcomes are presented.
Results
A total of 160 patients with EGFR‐mutated lung adenocarcinoma at clinical stages IIIB‐IVB received first‐ or second‐generation EGFR‐TKI frontline therapy. After disease progression, 82 patients were treated with osimertinib as a second‐line therapy with unknown T790M mutation status. Among them, 48 patients initially received afatinib as frontline treatment, while 34 patients received erlotinib. The best tumor response rate (RR) was 42.7%, with a median time on treatment (ToT) of 5.6 months (95% CI, 4.0–9.3). Swim‐plot visualization highlighted a hierarchical pattern wherein longer first‐line duration frequently co‐occurred with longer empirical second‐line duration.
Conclusion
Osimertinib treatment is a viable option for patients who progress on frontline first‐ or second‐generation EGFR TKI therapy without rebiopsy and have an unknown T790M mutation status. The RR of 42.7% and median ToT of 5.6 months appear consistent with historical outcomes reported for second‐line platinum‐based chemotherapy. Osimertinib provides an additional treatment line for patients whose tumors are difficult to access and have an unknown T790M status, making it a valuable treatment option for these patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Chest Medicine, Department of Internal Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Cancer Center, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
- Doctoral Program of Clinical and Experimental Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.
ORCID-Profile: Chiu-Fan Chen, Wei-Cheng Hong, Chun-Hsiang Hsu
Förderung
- Kaohsiung Veterans General Hospital
Zitieren
APA
Lin, M. H., Chu, K. A., Chen, C. F., Jiang, Y. C., Hong, W. C., Hung, M. Y., & Hsu, C. H. (2026). Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71881
Vancouver
Lin MH, Chu KA, Chen CF, Jiang YC, Hong WC, Hung MY, et al. Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71881
BibTeX
@article{Lin2026,
author = {Lin, Min-Hsi and Chu, Kuo-An and Chen, Chiu-Fan and Jiang, You-Cheng and Hong, Wei-Cheng and Hung, Ming-Yen and Hsu, Chun-Hsiang},
title = {Empirical Osimertinib as a Second‐Line Treatment Is a Viable Option Following First‐ and Second‐Generation TKI Therapy With Unknown EGFR Status in Treated Non‐Small Cell Lung Cancer: A Retrospective Study},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71881}
}
EUVIMED